NCT05983289View on ClinicalTrials.gov

Single Escalating Dose Study Of HSK7653 In Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

May 8, 2018

Primary Completion Date

July 3, 2019

Study Completion Date

July 3, 2019

Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
DRUG

HSK7653

HSK7653 tablets in six doses beginning at 5 mg and rising to 150 mg

DRUG

Placebo

Matching placebo tables in six doses beginning at 5 mg and rising to 150 mg

Trial Locations (1)

100032

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT05983289 - Single Escalating Dose Study Of HSK7653 In Healthy Subjects | Biotech Hunter | Biotech Hunter